Overview

Ipilimumab 12-month Intensive Pharmacovigilance Protocol

Status:
Completed

Trial end date:
2015-02-01

Target enrollment:

Participant gender:

Summary

The primary objective of the protocol is to identify and describe observed adverse events (AEs) while on treatment with Ipilimumab for advanced melanoma in Venezuela during the study period

Details

Lead Sponsor:

Bristol-Myers Squibb

Collaborator:

JSS Medical Research Inc.

Treatments:

Antibodies, Monoclonal
Ipilimumab